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BACKGROUND: Carboplatin remains a first-line agent in the management of epithelial ovarian cancer (EOC). Unfortunately, platinum-
resistant disease ultimately occurs in most patients. Using a novel EOC cell line with acquired resistance to carboplatin: PEO1CarbR,
genome-wide micro-array profiling identified the cyclin-dependent kinase inhibitor p57Kip2 as specifically downregulated in carboplatin
resistance. Presently, we describe confirmation of these preliminary data with a variety of approaches.
METHODS: Cytotoxicity testing (MTT) and cell cycle blockade assessed drug responsiveness. Methylation specific PCR and
pyrosequencing identified sites of promoter methylation in p57Kip2. siRNA to p57Kip2 was used to look at the changes in apoptosis of
carboplatin treated EOC cells. EOC tissues (20 cases) were assessed for mRNA levels of p57Kip2.
RESULTS: Carboplatin resistance was reversed using 5-aza-cytidine in vitro. Promoter methylation sites and preferential sensitivity to
seliciclib were seen in PEO1CarbR cells. Silencing p57Kip2 decreased the apoptotic response to the effects of platinum but produced
sensitisation to seliciclib. EOC biopsies indicated an association of high levels of p57Kip2mRNA with complete responses to
chemotherapy and improved outcome.
CONCLUSION: We conclude that p57Kip2 is a candidate biomarker of platinum sensitivity/resistance in EOC and such cases may show
preferential response to the cyclin-dependent kinase inhibitor seliciclib.
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p57Kip2 is a member of the CIP/KIP family of cyclin-dependent
kinase inhibitors (CDKI). Each member of this family possesses a
conserved domain at their N-terminus called the CDK binding-
inhibitory domain, unlike INK4 family members, which are
characterised by four tandem repeats of an ankyrin motif
(Beretta et al, 2005). In humans, the p57KIP2 gene is situated on
chromosome 11p15.5 in a cluster of imprinted genes such as
IGF-II and H19 (Beretta et al, 2005; Kim et al, 2005; Roeb et al,
2007). The gene is associated with a high frequency of
heterozygosity loss in human cancers and functions as a CDKI
by binding to cyclin E–CDK2 complexes, leading to inhibition of
G1 to S phase progression. Cyclin E–CDK2 is essential for pRb
phosphorylation and subsequent gene transcription by E2F. The
action of p57Kip2 on the cyclin E–CDK2 complex promotes cell-
cycle exit and cell differentiation. Differentiation signals have been
shown to induce accumulation of p57KIP2 mRNA (Roeb et al,
2007). P57Kip2 has a major role in embryogenesis predominantly in
early organogenesis, with ubiquitous expression in the whole
embryo, which decreases along with the increased embryo
development (Beretta et al, 2005). It is the only CDKI associated
with normal embryonic development, with loss of expression in
mouse embryos leading to defective proliferation in lens and
cartilage, and developmental defects in several tissues and
increased postnatal lethality (Zhang et al, 1998). Deficiency of
p57Kip2 in the mouse leads to organomegaly with abdominal wall
defects, increased apoptosis, delayed differentiation during devel-
opment, immaturity of some tissues, severe growth retardation
and placentomegaly (Kim et al, 2005). Loss of functional p57Kip2 is
also a common feature of rhabdomyosarcoma, even though it is
not a dominantly acting transforming event (Roeb et al, 2007) and
has also been reported for breast cancer, suggesting its role as a
putative tumour suppressor gene (Larson et al, 2008).
Cell-cycle dysregulation is a feature of many cancers, including
epithelial ovarian cancer (EOC) (D’Andrilli et al, 2004). Moreover,
dysregulation of cell-cycle components seems specific for certain
histological types of EOC. Serous EOC is the most commonly
observed subtype of this disease with a poorly understood
molecular aetiology. Overexpression of the CDKI p21Cip1/Waf11
has previously been shown to be associated with early-stage serous
tumours. Overexpression of p53 and cyclin E and reduced
expression of p27Kip1 and p21Cip1/Waf1 is associated with increasing
tumour grade (Bali et al, 2004). There are isolated reports
indicating lower p57Kip2 protein level in EOC tissue from patients
with a poor prognosis (Rosenberg et al, 2001).
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Previous work in our laboratory has involved the generation of
novel drug resistant models of EOC as part of an ongoing
programme to understand the basis for chemoresistance in this
disease. An initial microarray analysis of the human PEO1 human
EOC line and novel drug resistant variants revealed low levels of
the gene p57Kip2 as a consequence of carboplatin resistance.
Further, methylation reversal using demethylating agents sug-
gested a mechanism of gene silencing underlying the reduced
expression of p57Kip2 seen in carboplatin resistant cells. We have
further examined this initial finding using quantitative PCR
(qPCR) analysis, western immunoblotting of the same cell lines,
chemosensitivity testing and analysis of freshly extracted ovarian
cancer tissue for mRNA levels of p57Kip2 with assessment of
clinico-pathological features.
MATERIALS AND METHODS
Cell lines and culture conditions
The human ovarian cancer cell line PEO1 (kindly provided by
Dr F Balkwill, formerly of ICRF, London, UK) was grown in RPMI-
1640 medium (Sigma-Aldrich, Poole, UK) supplemented with 10%
heat-inactivated foetal calf serum (FCS) and 2mM Glutamax. All
cell culture reagents were obtained from Sigma (Poole, UK) unless
stated otherwise. The ovarian carcinoma cell line PEO1 (parental)
was cultured as a monolayer in RPMI-1640 medium and
supplemented with 10% FCS (heat inactivated; Invitrogen, Paisley,
UK) and maintained at low-passage number. The drug resistant
variants PEO1CarbR (carboplatin resistant) and PEO1CisR
(cisplatin) were derived by step-wise incubation of the chemother-
apeutic agent over a number of weeks. The maintenance dose for
PEO1CisR was 1 mM cisplatin and for PEO1CarbR 2 mM carboplatin.
These cell lines have previously been described (Coley et al, 2006).
Cytotoxic drugs
Cisplatin and carboplatin (Sigma) was dissolved as a stock solution
in sterile 0.9% saline and stored at 201C until use. 50-aza-20
deoxycytidine (obtained from Sigma-Aldrich) was made up in
sterile distiled water and stored at 201C in aliquots before use in
experiments. Seliciclib was obtained from Cyclacel Ltd (Dundee,
Scotland, UK) and from Selleck Chemicals (Houston, TX, USA),
made up in DMSO and stored as frozen aliquots.
Drug treatment of cells for methylation reversal
For the experiments that looked at the effects of demethylation on
platinum sensitivity and protein expression levels of p57Kip2,
prolonged exposure of demethylating drug was used for all cell
lines. The cultures were grown up for four to five passages in the
presence of 50-aza-cytidine at a dose of 1 mM for 5 days followed by
Trichostatin A 200 nM for 2 days (modified from the protocol
described by Syed et al, 2006), as repeated dosing with higher
doses gave rise to pronounced growth arrest and loss of viability,
particularly evident for the parental cell line. Note that the
carboplatin-resistant cells were not treated with their maintenance
dose of carboplatin during this time period. These cells were then
used in the MTT assay as shown in Figure 1C.
Cytotoxicity testing using the MTT assay
Cells for cytotoxicity testing were seeded into 96-well plates and
allowed to attach and equilibrate for 24 h in a humidifying
incubator at 371C and 5% CO2. They were then treated with
various concentrations of drug over two to three log orders of
concentration and left for 72 h to allow for approximately three to
four doublings (B10-fold increase in control cell number) over the
duration of the drug exposure. Drugs were diluted in tissue culture
medium containing 10% FCS. Control cell wells were treated with
an aliquot of drug-free tissue culture medium. Cell viability was
determined by addition of 4 104mg MTT (thiazoyl blue
tetrazolium bromide; Sigma-Aldrich) for 4 h at 371C. Wells were
aspirated to remove the medium and the resulting formazan
crystals solubilised in 200ml DMSO and the absorbance read at
570 nM. The absorbance of the formazan product obtained for
drug-treated cells was calculated as a fraction of that for the
untreated control wells. Growth curves were constructed using
PRISM software (GraphPad Software Inc., La Jolla, CA, USA) and
results expressed as IC50 values, that is, dose of drug causing a 50%
reduction in cell viability.
Assessment of cell-cycle perturbations following seliciclib
treatment of ovarian cancer cells
Cells were seeded in culture flasks, and incubated for 24 h, before
treatment with seliciclib (25mM) for 48 h. This corresponded to the
cells being in early-exponential phase of growth, B30–40%
confluent. At the end of the treatment period, cells were removed
by trypsinisation, centrifuged and the pelleted cells were washed in
PBS and resuspended in ice-cold 70% ethanol in PBS (added slowly
whilst vortex mixing). Samples were left at 41C for at least 24h. After
washing in PBS, cells were stained in 5mgml1 propidium iodide
(PI) and 1mgml1 ribonuclease A for at least 30min at 371C in the
dark. Fluorescence at 575nm (FL3) was measured on a Beckman-
Coulter Epics XL flow cytometer. Cell-cycle phases were evaluated
using the Multi-Cycle software program (Beckman Coulter, High
Wycombe, UK).
Assessment of apoptotic response following silencing of
p57KIP2
Cells were cultured in six-well plates before transfection with
siRNA against p57KIP2 (obtained from Dharmacon, ThermoFisher,
Epsom, UK). The process was carried out according to manu-
p5
7K
IP
2  
m
R
N
A 
ex
pr
es
sio
n
re
la
tiv
e 
to
 a
ct
in
×
10
–
3
0.1
0.0
0.2
0.4
p57kip2
Actin
PE
O1
PE
O1
Cis
R
PE
O1
Ca
rbR
PE
O1
+A
za
PE
O1
Cis
R+
Az
a
PE
O1
Ca
rbR
+A
za
0.3
PEO1 PEO1CisR PEO1CarbR
Figure 1 (A) Western immunoblotting of PEO1 cell lines without and
with 5-aza-2-deoxy-cytidine/trichostatin A treatment (þ aza) using SDS–
PAGE gels (NOVEX system, Invitrogen) followed by western transfer onto
PVDF membranes. Membranes were probed with a primary rabbit
polyclonal antibody to p57kip2 sc-8298 (clone H-91) (Santa Cruz,
distributors Autogen Bioclear, Calne, UK). Membranes were stripped and
reprobed for actin as a loading control. (B) Expression levels of mRNA
p57Kip2 in the PEO1 panel of cell lines obtained qPCR with SyBr green and
actin as the internal control. Data shown are the mean (and s.d.) for at least
three repeat experiments.
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facturer’s instructions and cells were left to grow for 72 h, using
appropriate controls. After this time, cells were harvested and
seeded into 25-cm2 flasks to B40% confluence. After attachment,
the cells were then treated with various doses of carboplatin and
with seliciclib for a period of 48 h. The doses of drug are indicated
in the appropriate legend. Cells were then harvested and subjected
to the Annexin V assay combining with PI according to
manufacturer’s instructions (CN Biosciences, Beeston, UK).
Samples were then subjected to flow cytometry, using FL1 for
FITC conjugated Annexin and FL3 for PI on the Coulter EPICS
flow cytometer.
DNA isolation
DNA was extracted from cell lines with and without treatment with
the demethylating agent 5-Aza-20deoxy-cytidine 5 mM and with
Trichostatin A 200 nM for successive passages, as described above.
This was carried out using the GenElute genomic DNA kit (Sigma-
Aldrich) according to manufacturer’s instructions.
Methylation specific PCR (MSP)
Methylation specific PCR was carried out using 1 mg of genomic
DNA with bisulphite modification using the EZ DNA methylation
kit (Zymo Research; obtained from Cambridge Biosciences,
Cambridge, UK) according to manufacturer’s instructions. For
each assay set up a control universal methylated DNA standard
(Zymo Research; Cambridge Biosciences) was also taken through
the process to ensure that bisulphite conversion was complete.
Primers were designed using the MethPrime program (http://
itsa.ucsf.edu/?urolab/methprimer). The PCR for the p57KIP2 CpG
island was performed using HotStart Mastermix (Qiagen Ltd,
Crawley, UK) using a thermal cycler with the following protocol:
951C for 15min; 40 cycles of: 951C for 30 s, 521C for 30 s, 721C
for 30 s, for the U (unmethylated sequence) and 951C for 15min;
40 cycles of 951C for 30 s, 591C for 30 s and 721C for 30 s for the M
(methylated sequence).
The sequences for the primers (U; M) were as follows:
Left M primer: 50-TGTAGTTCGCGGTTTAGTTTTTC-30
Right M primer: 50-ATCCACGATAAAACGTCTTATCG-30
Product size: 50-114 bp
Left U primer: 50-TTTGTAGTTTGTGGTTTAGTTTTTT-30
Right U primer: 50-ACATCCACAATAAAACATCTTATCA-30
Product size: 50-118 bp
PCR reactions were carried out on at least three separate
occasions and the products then visualised using 0.8% agarose
separation with TAE buffer with ethidium bromide staining and
transillumination.
DNA methylation analysis using pyrosequencing
2 mg of DNA was bisulfite-converted using Qiagen Epitect Bisulfite
Conversion kit and following the manufacturer’s protocol. The
bisulfite-converted DNA was eluted from the column to 40 ml final
volume. For pyrosequencing PCR, 2 ml of the bisulfite-converted
DNA was used in a final 50 ml reaction volume. The PCR cycle used
was: 951C for 15min; 50 cycles of: 951C for 30 s, 601C for 30 s, 721C
for 30 s and 721C for 5min. The pyrosequencing was carried out
using the Biotage PSQ96MA pyrosequencer (Biotage AB, Uppsala,
Sweden). The primers used were:
Forward primer: 50-AGGGGAGGGTTGATAGTTA-30
Biotinylated reverse primer: Bio50-CTAAAATTACCACTTCCAA
CAAAACATACC-30
Sequencing primer: 50-GGGGAGGGTTGATAGTTAT-30
The primers were designed using Pyromark Assay Design Software
2.0 (Qiagen Ltd) to match the region targeted by MSP primers.
The primer design was targeted from 1301 to 1700 bases of the
UCSC Genome Browser March 2006 (NCBI36/hg18) annotated
CpG island191. The final primers selected had a score of 77 and
were passed through the software quality control. The PCR
product size was 117 bp. The sequencing primer covered 17 target
polymorphisms/CpG sites.
Western immunoblotting
Whole-cell lysates were obtained by trypsinising the monolayer
of adherent cells and washing with PBS at 41C. Cell pellets
were then subjected to osmotic rupture in hypotonic detergent
based buffer (1mM PMSF, NaVO4, aprotinin and leupeptin as
protease inhibitors, 150mM NaCl, in 50mM Tris buffer, 0.2% SDS,
1% NP-40, pH 7.5) and 50mg of protein per sample electro-
phoresed on SDS–PAGE gels with subsequent transfer blotting.
Membranes were incubated overnight at 41C with primary antibody.
After washing, membranes were incubated with a secondary
horseradish peroxidase-linked appropriate species antibody pre-
paration at room temperature for 1h followed by chemiluminescence
for visualisation. Following the probing of each membrane with the
primary antibody, the membrane was stripped and reprobed using
an actin antibody to act as a loading control.
Clinical samples and correlation with outcome
Clinical cases of EOC were obtained by informed consent by the
Section of Gynaecological Oncology and by local ethical committee
approval, St Luke’s Cancer Centre, Royal Surrey County Hospital
(Guildford, Surrey, UK). In each case, the diagnosis and presence
of adequate tumour representation in the specimen was confirmed
by histopathological analysis. The histological classification for the
samples was shown to be: serous (13 cases); clear cell, including
those with mixed endometrioid histology (1þ 2 cases); mixed
Mullerian tumour (1 case) and endometrioid (2 cases). As all these
women underwent primary surgery at the time of sample
collection, they then received six cycles of postoperative che-
motherapy, which included combination of carboplatin and
paclitaxel or a single agent carboplatin only depending on their
performance status. Follow-up and mature data including response
to treatment, disease free interval and overall survival is also
recorded. Assessment of response to treatment included clinical
examinations, serum CA 125 levels and computerised tomography
scans when indicated. Patients were classified as complete, partial
and non-responders based on the above three criteria, which in
turn depended on the bulk of residual disease following surgery.
Minimal residual disease with normal CA 125 indicated a complete
response (CR). A measurable reduction in disease by X30% on
clinical and radiological examination constituted a partial
response (PR). Progression on treatment or relapse within 6
months suggested a non-response.
Collection and RNA extraction of ovarian cancer biopsies
Tissue was obtained at first laparotomy before chemotherapy and
then rapidly frozen at 801C for short-term storage before
extraction. The frozen biopsies in RNALater solution (Qiagen
Ltd) were thawed on ice and preservation fluid aspirated. RNA was
isolated using the RNeasy method (mini-column procedure;
Qiagen Ltd) with sample lysis using the TissueLyser (Qiagen
Ltd). The quality of the resulting RNA was checked with an Agilent
2100 Bioanalyser using an RNA NanoLabchip according to the
manufacturer’s instructions (Agilent Technologies UK Ltd, Stock-
port, Cheshire, UK). The RNA was diluted with RNase free water
and quantified using the Nanodrop spectrophotometer (Nanodrop
Technologies Inc., Fisher Scientific, Loughborough, UK). Follow-
ing verification of the quality of RNA extracted, 19 samples were
deemed suitable for further analysis.
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Real-time PCR for p57Kip2 in ovarian cancer cell lines and
clinical biopsies of EOC
cDNA was synthesised from 2 mg of total RNA. PCR was performed
in an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems, Life Technologies Ltd, Paisley, UK) using the dye
SyberGreen qPCR mastermix (Qiagen Ltd). Primers for p57Kip2
were obtained from SuperArray (Tebu-Bio, Leicester, UK) with gene
identification of CDKN1C (NM_000076). Primers for actin were
obtained from Invitrogen. Sequences were: forward: 50-GCATCCAC-
GAAACTACCTTC-30; reverse: 50-CAGGAGGAGCAATGATCTTG-30.
For qPCR reactions, 1.5mM MgCl2 was used for all primers
(p57Kip2 and actin) and the cycling conditions used were: 40 cycles
at 951C for 30 s, 581C for 30 s and 721C for 40 s. Fold inductions
were calculated using the formula 2(DDCt), where DDCt is the DCt
(p57
Kip2
) -DCt (actin) and Ct is the cycle at which the threshold is crossed.
Statistical analysis
Expression levels of mRNA for p57Kip2 of the groups of samples
split into categories, which can be described as CR, PR and NR (no
response) were assessed using a one-way ANOVA using Minitab.
The CR group was compared with the PR and NR group combined
because of the small sample size for the latter group. The survival
times of the different groups were compared using a log rank test
using SPSS Version 12 software (SPSS Inc., Chicago, IL, USA).
Other t-tests were performed to compare IC50 doses obtained from
dose-response curves and these are quoted as appropriate.
RESULTS
Cell lines
We have previously derived a novel cell line with acquired
resistance to carboplatin, PEO1CarbR, from the PEO1 parental cell
line, as described (Coley et al, 2006). We have also included the
PEO1CisR (cisplatin-resistant variant) for comparison in some
experiments.
p57Kip2 is epigenetically downregulated in carboplatin-
resistant EOC cells
To seek genes differentially expressed between parental and drug
resistant cell lines, we performed an initial microarray expression
analysis screen (data not shown). We observed a marked reduction
in p57Kip2 expression in the PEO1CarbR cells and thus set about
confirming the protein expression and mRNA levels. We
performed qPCR and western blot analysis of p57Kip2 expression
in the PEO1 parental, cisplatin-resistant and carboplatin-resistant
cell lines. These experiments showed that p57Kip2 mRNA (and
protein) levels were greatly reduced in PEO1CarboR relative to the
parental PEO1 cells (Figure 1A and B). For PEO1CisR cells we saw
that expression of p57kip2 levels fluctuated but generally the levels
were similar or higher than the parental PEO1 cell line.
Demethylation increases p57kip2 expression in carboplatin-
resistant cells
The initial microarray assay incorporated a pre-treatment step
with aza-cytidine and zebularine (both demethylating agents) for
comparison of gene expression levels with untreated cells. We saw
evidence of unmasking of the p57kip2 gene expression levels In
order to corroborate this initial observation we tested whether
treatment with 5-aza-20deoxy-cytidine restored p57kip2 protein
expression levels in the cell line panel. We demonstrated that at the
protein level demethylation treatment can unmask the expression
of p57kip2 in the PEO1CarbR line, with no significant effect being
seen for the parental or PEO1CisR line, as shown in Figure 1A.
Drug sensitivity of PEO1 lines and effects of demethylation
treatment to carboplatin and seliciclib
Given the association of p57kip2 with CDK2 and cyclin E we
considered the use of a selective CDK2 inhibitor drug as a possible
treatment strategy in p57kip2 deficient cells. Using the MTT assay
with continuous drug exposure (72 h) we saw that PEO1CarbR cells
showed preferential sensitisation to seliciclib in comparison with
PEO1 parental and PEO1CisR cells based on IC50 values: PEO1
26.4mM (/þ 3.51), PEO1CisR 33.0mM (/þ 2.71) and PEO1-
CarbR 16.0 mM (/þ 2.06), Po0.005 (using a one-tailed paired
test) comparing IC50 value for PEO1CarbR with either PEO1 or
PEO1CisR. Dose-response curves for the PEO1 lines treated with
seliciclib are shown in Figure 2A.
We then used a similar epigenetic reversal treatment protocol as
in western blotting experiments (Figure 1A) and assessed drug
sensitivity following this. 5-Aza-20deoxy-cytidine had a negligible
effect on sensitivity to either carboplatin or seliciclib in parental
PEO1 cells (IC50 values not changed by 410%, data not shown).
For the time period we used the epigenetic reversal protocol
(c. 4 weeks), the drug resistant variant maintained a drug resistant
phenotype in parallel cultures, under standard culture conditions
(in the absence of the demethylating agent), indicating that the
resistance phenotype was stable for the study period in the absence
of the inducing agent (carboplatin). As depicted in Figure 2B, the
IC50 values (mM) following treatment of cells with continuous
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Figure 2 (A) Dose-response curves for PEO1 (circle), PEO1CisR
(triangle) and PEO1CarbR (square) treated with seliciclib (n¼43, with
the s.d. shown for each data point (drug concentration used) as error bars).
(B) IC50 data obtained from dose-response curves (using MTT) with
continuous drug exposure for PEO1 parental (black), PEO1CarbR (vertical
shading), PEO1CarbR demethylated (white) and PEO1CisR (horizontal
shading) for carboplatin and for seliciclib treatments. All experiments were
carried out on at least three separate occasions and data show the IC50 as
mean with s.d. as error bars, P-values obtained for comparison of IC50
values for PEO1CarbR cells versus PEO1CarbR-demethylated cells were
0.0055 (*) for carboplatin and 0.016 (**) for seliciclib (paired t-test). For
carboplatin the resistance factors obtained for PEO1CarbR was 4.2 and for
PEO1CarbR-demethylated was 2.2.
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exposure to carboplatin were as follows giving the mean and (s.d.)
for at least three separate replicate analyses: PEO1 22.7 (7.8),
PEO1CarbR 94.3 (26.4) and PEO1CisR 98.7 (16.7). In addition, for
the PEO1CarbR-demethylated cells the level of carboplatin
resistance was reduced with a shift in IC50 down to 49.2mM
(P¼ 0.0055 using a one-tailed paired test). In the same experi-
ments we saw that the level of seliciclib sensitivity was reduced in
the PEO1CarbR-demethylated cells going from 16.0 to 23.3mM
(P¼ 0.016 using a one-tailed paired test) following unmasking
of p57kip2.
Carboplatin–resistance associated with p57Kip2 silencing
gives rise to collateral sensitivity to the CDKI seliciclib,
which is shown by a prolonged S-phase
Treating asynchronous cultures of the PEO1 panel of cell lines with
a 25 mM dose of seliciclib gave rise to cell-cycle perturbations,
as seen in Figure 3, with the biggest differences being seen for
PEO1CarbR in terms of the decrease in G1 (P-value 0.005 and 0.003
for PEO1CarbR and PEO1CisR, respectively using a one-tailed
paired test) and concomitant increase in S-phase: P-value 0.03 for
PEO1CarbR, PEO1 0.26 and PEO1CisR 0.24, comparing control
and treated cells using a one-tailed paired t-test). Statistical
analysis of the sub-G1 populations of cells comparing untreated
controls and following seliciclib treatment produced P-values that
were for PEO1 0.05, PEO1CarbR 0.06 and for PEO1CisR 0.15 (using
a one-tailed paired test). Thus, the S-phase change following
treatment emerged as the best indicator of sensitivity to seliciclib.
AnnexinV experiments using flow cytometry were also carried out
and support the finding for a greater apoptotic response seen for
seliciclib treated PEO1CarbR cells compared with PEO1 cells (data
not shown), in line with the cytotoxicity data.
Detection of methylation specific site in p57kip2 in
carboplatin-sensitive and -resistant ovarian cancer cells
Reversal of p57Kip2 silencing by 5-aza-20deoxy-cytidine implies that
methylation-dependent transcriptional silencing may underlie the
reduced expression in PEO1CarboR. To directly address this
possibility, we performed MSP analysis of the CpG island in the
50 region of the p57KIP2 gene. Following PCR the resulting products
were run on an agarose gel and visualised using ethidium bromide
staining with transillumination. For the PEO1CarbR cells the level
of methylated (M) p57kip2 was shown to be significant, with a very
small band seen for the unmethylated (U) DNA, whereas for the
PEO1 parental cells the predominant form of p57kip2 was seen to be
of the unmethylated form. Treatment with aza-cytidine revealed a
marked increase in the unmethylated form of p57kip2 for
PEO1CarbR cells, Figure 4A. This corroborates the data obtained
for protein expression as shown in the western blotting data,
Figure 2A. Using the sensitive method of pyrosequencing, we were
able to detect the exact level of methylation at each CpG location
along the sequence positions 1361–1445, which matches well with
the sequence we examined using MSP (1407–1520) (Figure 4B).
The level of methylation for PEO1CarbR was shown to be
significantly higher than for PEO1, P¼ 0.026 and for PEO1CisR
the levels of methylation were not significantly different from the
parental cell line (P-value 0.285 using a paired t-test, data not
shown).
Silencing of p57Kip2 results in a decreased apoptotic
response to platinum
Data shown in Figure 5A indicate the changes in apoptotic effects
seen in at 48 h post-treatment in drug treated EOC cells following
silencing with siRNA to p57Kip2. All experiments were carried out
at least three times on PEO1 parental cell lines (not shown).
Statistically significant decrease in apoptotic responses to carbo-
platin and increase in apoptotic response to seliciclib were seen in
silenced versus control cells, see the legend to Figure 5A, which
indicates cells in the viable region of the quadrant plot for the
Annexin assay (lower left), expressed as a percentage of the
untreated control cell viability (considered as 100%). Figure 5C
shows the consistent lack of apoptosis induction for the p57kip2-
silenced cells over the dose range of 100–200mM carboplatin
treatment for 48 h. Comparison of control and transfected drug
treated cell viabilities was carried out using the paired t-test
(indicated in the figure legend). Similar experiments were carried
out on SKOV-3 parental cells and the effects of p57kip2 silencing
gave very similar (statistically significant) shifts in sensitivities to
carboplatin and to seliciclib as seen for transfected PEO1 cells
(data not shown).
80
+ Seliciclib + Seliciclib
*
+ Seliciclib
60
40
20
%
 c
el
ls 
in
 c
yc
le
 p
ha
se
0
PEO1 PEO1CisRPEO1CarbR
Figure 3 Cell-cycle analysis for PEO1 cell lines treated with seliciclib
(25 mM) for 48 h. Key: SubG1, white; G1, black; S-phase, grey; G2M,
horizontal line. N¼ 3 separate experiments. Cells were stained with PI
(see Materials and Methods) and analysed used a Coulter Epics flow
cytometer with data analysis using MultiCycle software (Beckman Corp.).
The S-phase for treated PEO1CarbR cells versus control gave a P-value
of 0.03, indicated as *.
PEO1 parental
U + aza M
PEO1CarbR
carboplatin resistant
100
80
60
40
20
0
CpG location
1 7 9 11 13 15 173 5
%
 M
et
hy
la
tio
n
Figure 4 (A) Methylation specific PCR analysis for PEO1 and
PEO1CarbR lines in the absence or presence of azacytidine (þ aza)
for the unmethylated portion (U) and for the methylated portion (M).
Results shown are typical for those obtained in replicate experiments
(n¼ 4). (B) Pyrosequencing for detection and quantitation of methylation
in the promoter region of the p57Kip2 gene with extent of methylation
obtained from pyrosequencing analysis shown on the y-axis. Black bar
indicates the parental PEO1 line; white bar indicates PEO1CarbR
carboplatin resistant line.
p57Kip2 status predicts carboplatin sensitivity
HM Coley et al
486
British Journal of Cancer (2012) 106(3), 482 – 489 & 2012 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
Clinical samples of EOC showed downregulation of p57Kip2
mRNA which was associated with worse outcome
Statistical analysis of the data obtained from the qPCR analysis of
RNA obtained from surgical samples of ovarian cancer showed a
significant increase in survival for those cases where there was a
CR to platinum-based chemotherapy compared with the other
cases. A one-way ANOVA analysis for comparing p57Kip2 mRNA
expression with a CR compared with partial and non-responders
combined within the entire data set, which includes all the
histological types, showed a significant difference: P-value of 0.034,
Figure 6. In the data set obtained there was a significant increase in
survival time (measured in months and for all histological types)
associated with response to therapy (P¼ 0.002 using a one-way
ANOVA (data not shown).
DISCUSSION
There is increasing evidence that acquired resistance to cytotoxic
chemotherapeutic drugs is driven by epigenetic rather than genetic
mechanisms (Glasspool et al, 2006). Moreover, anticancer drug
resistance is probably better described as a polygenic condition/
state whereby many factors may be operative in one patient. The
inactivation of many genes with important functions, such as
tumour suppressor genes, has shown that aberrant methylation
has an important role in human carcinogenesis. The data we
provide in the current study explore this further in terms of
evolution of drug resistance in difficult-to-treat cancers – notably
EOC.
Moreover, we propose that p57Kip2 has a pivotal role in the
chemo-responsiveness of EOC particularly in relation to platinum
containing regimens – specifically for carboplatin. Methylation of
p57KIP2 has been implicated in a number of malignant conditions,
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for example, the lung, breast and malignant mesotheliomas
(Kobatake et al, 2004). However, to our knowledge, the role
of this gene in anticancer drug resistance has not been reported
until now.
Our study has made use of a panel of EOC lines with resistance
to carboplatin, but we also used a cisplatin-resistant counterpart in
parts of the study. Our study clearly shows that the association of
drug resistance with downregulation of the p57kip2 gene and
collateral sensitivity to the CDK2 inhibitor seliciclib was seen
exclusively for the carboplatin-resistant cell line in our panel.
Notwithstanding, we see cross-resistance to carboplatin in the
PEO1CisR cisplatin-resistant line – but this is in the absence of
p57kip2 downregulation and without concomitant relative sensitiv-
ity to seliciclib. The development of resistance to cancer
chemotherapeutic drugs can result in cell lines with mixed and
complex resistance phenotypes – even using the same class of
chemotherapy drug as an inducing agent, such as platinum agents
(Song et al, 2004).
A study by Vlachos et al (2007) indicated the importance of
p57Kip2 in the commitment of drug-treated HeLa cells to drug-
induced apoptosis and lends support to the role of this CDKI in
response to anticancer drug therapy. Using an inducing transfec-
tion system it was shown that selective expression of p57KIP2sensi-
tised cancer cells to the mitochondrial pathway of apoptosis
following treatment with cisplatin, etoposide and staurosporine.
Interestingly, the mechanism was shown to operate separately
from any activity of p57Kip2 relating to its CDK inhibitory activity
(although the sensitivity to seliciclib, at least in this system,
suggests a CDK-dependent mechanism). Thus, this study corro-
borates the findings of the current study that equates a reduced
expression of p57Kip2 with a more chemoresistant phenotype.
Indeed, we did see a reduced sensitivity of p57kip2-silenced cells to
the effects of cisplatin, as well as to carboplatin (data not shown).
Our findings that ovarian cancer cells with silenced p57Kip2 are
more sensitive to the effects of the CDKI seliciclib are in keeping
with the findings of Ma and Cress (2007). MDA-MB-231 cells
deficient in p57Kip2 (using shRNA) were significantly more
sensitive to the effects of the CDK2 inhibitor BMS-387032 in a
similar manner to that seen for PEO1CarbR cells treated with
seliciclib. In the same study it was shown that exogenous
expression of p57Kip2 cells led to a decreased fraction of cells in
the S-phase and repression of E2F1 transcription following
treatment with BMS-387032. This is in line with our findings that
p57Kip2 deficient PEO1CarbR cells are sensitised to the effects of
seliciclib as shown by an enhanced apoptotic response and
cytotoxicity.
The CDKIs have been implicated in the pathogenesis of ovarian
cancer – with the expression of p27Kip1, but not p21Waf1 being
associated with response to chemotherapy. Masciullo et al (1999)
showed that p27Kip1 positivity was a strong predictor of survival,
and was strongly associated with response to chemotherapy in
those patients who were optimally debulked at the time of their
first surgery. However, the expression of p21Waf1 was not
associated with response to platinum agents or other chemo-
therapy in a group of 120 patients with EOC (Levesque et al, 2000).
The present study shows in vitro evidence that measurement of
p57Kip2 may be a useful prognostic indicator in EOC.
As well as genes such as methylation of p57Kip2, it is likely that
many other events will contribute to the process of drug resistance
in a given case of EOC. This is in line with studies published by
other groups that have used clinical biopsies of EOC to monitor
changes in CpG islands as a marker of disease progression (Wei
et al, 2002). Serum or plasma from cancer patients often contains
identical DNA changes to those present in the tumour and can thus
provide a means for monitoring epigenetic changes within an
individual tumour in a surrogate sample. We have recently
completed a study involving matched blood and tissue from
patients with EOC who were clearly defined into two cohorts of
either relapsing or non-relapsing. We have gone on to measure the
serum and plasma DNA for another gene – associated with the
polo-like kinases and G2-checkpoint control – in those patients
and have seen a statistically significant association between
methylation status and relapse (Syed et al, 2011). As a continuation
of the study presented herein our future studies involving p57Kip2
will involve measurement of methylated p57KIP2 DNA in tumour
tissue and matched serum from a large cohort (4200) of ovarian
cancer patients. We therefore plan to explore the utility of
methylated p57KIP2 DNA as a prognostic indicator in ovarian
cancer. Moreover, our data suggest that p57Kip2 could be used as a
marker of sensitivity to the cell-cycle inhibitor seliciclib.
In conclusion, we present data that contribute to our under-
standing of drug resistant EOC and support the notion that this
process can be explained on the basis of epigenetic modification,
involving the CDKI p57Kip2. Moreover, our approach will help in
the identification and evaluation of new prognostic markers for the
management of EOC.
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